A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07644351
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.

Key Dates

First listed
Jun 12, 2026
Start date
Dec 16, 2024
Status verified
Jun 2026
Primary completion
Sep 17, 2025
Completion
Sep 17, 2025

Study Design

Enrollment
37 participants (actual)

Arms

  • Arm: Asciminib Cohort
    Ph+ ALL patients who received at least one dose of asciminib through the asciminib MAP.

Primary Outcome Measure

Proportion of Patients Achieving Hematological Complete Remission (CR) or Hematological Complete Remission With Incomplete Count Recovery (CRi) in the First 3 Months of Treatment [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Novartis Investigative SiteBostonMassachusetts02115-

Find similar trials in Boston, MA

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials
By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Novartis Investigative Site· Boston, MA

Related Studies